Europe approves Merck’s plant to make J&J COVID-19 vaccine

Related Articles

imageStock Markets12 minutes ago (Oct 07, 2021 06:06PM ET)

(C) Reuters. FILE PHOTO: FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo/File Photo/File Photo

(Reuters) – The European Medicines Agency (EMA) said on Thursday it had approved U.S. drugmaker Merck & Co Inc’s manufacturing site in West Point, Pennsylvania to make Johnson & Johnson (NYSE:JNJ)’s COVID-19 vaccine.

Earlier this year, Merck agreed to make its rival’s shot, after scrapping two of its own experimental COVID-19 vaccines.

The U.S. government at that time invoked the Defense Production Act to help equip two Merck plants to make the J&J vaccine.

The EMA said Merck’s site, to become operational immediately, was expected to support the continued supply of J&J’s COVID-19 vaccine in the European Union.

Europe approves Merck’s plant to make J&J COVID-19 vaccine

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Popular stories